AVR

MKT CAP:$205M

Anteris Technologies Global Corp.

Market Cap

$205M

Healthcare·Medical - Devices·🇦🇺 Australia·NASDAQ

Healthcare·Medical - Devices·🇦🇺·NASDAQ

Stock Price

$5.53+$0.61 (+12.40%)

Apr 23, 2026

Company Details

Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter ...

CEO

Wayne Geoffrey Paterson

IPO Date

Dec 13, 2024

Website

anteristech.com

Key Metrics TTM

Revenue

$2M

-30.3% YoY

Net Income

-$84M

EPS (Diluted)

-$3.58

Free Cash Flow

-$79M

Revenue / Share

$0.09

Gross Margin

67.9%

Operating Margin

-4020.0%

Net Margin

-3941.7%

FCF Margin

-3713.4%

P/S

95.8x

P/E

—

Earnings Reports

Q4 2025

May 12, 2026

PENDING

FY 2025

Feb 26, 2026

$2M-29.2%EPS -$4.00

Q3 2025

Nov 12, 2025

$429.0K-44.2%EPS -$0.94

Q2 2025

Aug 11, 2025

$618.0K-2.1%EPS -$0.89

Q1 2025

May 13, 2025

$556.0KEPS -$0.93

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 23	$1M	$714.7K	-$11M
Q3 23	$599.0K	$43.1K	-$11M
Q2 24	$631.5K	$319.4K	-$19M
Q3 24	$769.0K	$325.4K	-$22M
Q4 24	$536.1K	$328.4K	-$21M
Q1 25	$556.0K	$349.0K	-$22M
Q2 25	$618.0K	$470.0K	-$21M
Q3 25	$429.0K	$306.0K	-$22M

Valuation

Quarter	P/S	P/E
Q1 23	—	—
Q3 23	—	—
Q2 24	—	—
Q3 24	42.2x	—
Q4 24	51.9x	—
Q1 25	34.4x	—
Q2 25	36.0x	—
Q3 25	48.1x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$10M	-$11M
Q3 23	-$9M	-$9M
Q2 24	-$13M	-$14M
Q3 24	-$14M	-$15M
Q4 24	-$18M	-$19M
Q1 25	-$21M	-$22M
Q2 25	-$20M	-$20M
Q3 25	-$18M	-$19M

Capital Expenditures

Quarter	CapEx
Q1 23	$843.7K
Q3 23	$719.6K
Q2 24	$646.7K
Q3 24	$553.1K
Q4 24	$363.1K
Q1 25	$248.0K
Q2 25	$537.0K
Q3 25	$772.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 24	-50.0%	+82.7%
Q1 25	-7.2%	+89.3%
Q2 25	-2.1%	+10.2%
Q3 25	-44.2%	+0.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$2M	175.3%
Q3 23	$1M	203.4%
Q2 24	$2M	268.3%
Q3 24	$2M	262.6%
Q4 24	$0	0.0%
Q1 25	$2M	280.8%
Q2 25	$2M	256.5%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$7M	$5M
Q3 23	$8M	—
Q2 24	$13M	$6M
Q3 24	$14M	—
Q4 24	$13M	—
Q1 25	$16M	—
Q2 25	$16M	—
Q3 25	$17M	—

Revenue by Geography

Quarter	Australia	Germany	United States
Q1 25	$8.0K	$271.0K	$277.0K
Q2 25	$8.0K	—	$610.0K
Q3 25	$9.0K	—	$420.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 23	$13M	$0	$13M
Q3 23	$13M	$0	$13M
Q4 23	$21M	$0	$21M
Q1 24	$7M	$0	$7M
Q2 24	$7M	$0	$7M
Q3 24	$10M	$0	$10M
Q4 24	$70M	$0	$70M
Q1 25	$49M	$0	$49M
Q2 25	$28M	$0	$28M
Q3 25	$9M	$0	$9M
Q4 25	$13M	$0	$13M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 23	36M	—	—
Q3 23	36M	0.0%	—
Q2 24	36M	0.0%	—
Q3 24	36M	0.0%	—
Q4 24	24M	-34.4%	-34.4%
Q1 25	24M	0.0%	-34.4%
Q2 25	24M	0.0%	-34.4%
Q3 25	24M	0.0%	-34.4%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 23	—	—
Q3 23	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	$3.9K	136
Q1 25	$4.1K	136
Q2 25	$4.5K	136
Q3 25	$3.2K	136

Revenue / Employee